Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid
| WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid. In mid-2020, the company announced its own investments to increase pipette tip production capacity to support COVID-19 testing.
With the DoD award, issued on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), Thermo Fisher will co-invest with the U.S. government in building a new, state-of-the-art, energy efficient manufacturing facility for pipette tips, which are used in vital disease research and in high volumes for processing of diagnostic tests nationally, including COVID-19, during the pandemic. The new center of excellence in laboratory consumables manufacturing and operations will be in North Carolina and designed in line with Thermo Fisher’s carbon neutrality goals. Construction will be fully completed by Q3 2024, with pipette tip manufacturing starting as early as Q3 2023. The site, expected to create hundreds of new jobs in the region, has the potential for future expansion across a variety of high-demand product lines. “This award and the resulting capacity ensure that future demand surges in the U.S., from the current COVID-19 pandemic to the next crisis, will be met with greater supply assurance,” said Mark Stevenson, executive vice president and chief operating officer. “Supply chain agility is critical to our customers, our government and to the health and safety of our citizens, and we’re excited to bring this state-of-the-art capacity online, especially since its efficient design will also showcase our commitment to achieve net-zero carbon emissions by 2050.” Laboratory consumables have been vital in global COVID-19 mobilization, from sample collection vials for diagnostic test kits to lab plastics and materials for vaccine production and biobanking. Since the start of the pandemic, Thermo Fisher has invested more than $180 million to expand its laboratory plastics consumables production and another $600 million to increase global bioprocessing capacity. In addition, the company opened new sites dedicated to manufacturing viral transport media used in COVID-19 sample collection and cGMP plasmid DNA used in mRNA-based vaccines. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com. Media Contact Information: Investor Contact Information:
SOURCE Thermo Fisher Scientific | ||
Company Codes: NYSE:TMO |
View original content to download multimedia:
